At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
BOTOX® purified neurotoxin complex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
In Brief
A Phase 2 clinical trial evaluating BOTOX® purified neurotoxin complex and Placebo for Platysma Prominence. Completed, enrolled 171 participants across 12 sites in 2 countries.
Detailed Summary
To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatysma Prominence
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedApr 16, 2019
Enrollment StartApr 23, 2019
Primary CompletionApr 16, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.2 years ago
Interventions
BOTOX® purified neurotoxin complexdrug
BOTOX® superficial intramuscular injections.
Placebodrug
Placebo injections.